Avid Bioservices: Capitol Biologics Launches CDMO for Biopharmaceutical Manufacturing Solutions
- Capitol Biologics, launched by BioFactura, offers comprehensive manufacturing solutions for biologics, enhancing support for biotechnology companies.
- The division adheres to strict global regulatory standards, ensuring compliance and high-quality products for clients in the biopharmaceutical sector.
- Capitol Biologics aims to foster collaboration and innovation, positioning itself as a vital partner in advancing health solutions.
Capitol Biologics: A New Player in Biopharmaceutical Manufacturing
BioFactura, Inc., a clinical-stage biopharmaceutical company based in Frederick, Maryland, launches Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO). This strategic initiative aims to provide robust support for biotechnology companies and U.S. government agencies in their development and manufacturing pursuits. By establishing Capitol Biologics in the BioHealth Capital Region, the company positions itself within proximity to key pharmaceutical hubs and government facilities, enhancing logistical efficiencies and collaborative opportunities.
With over two decades of expertise in biologics, BioFactura's Capitol Biologics offers comprehensive phase-appropriate manufacturing solutions tailored for monoclonal antibodies, recombinant proteins, and complex biologics. The division is designed to adhere strictly to global regulatory standards, including those set by the FDA and EMA, ensuring that clients receive high-quality products that meet the necessary compliance requirements. This commitment to quality is further emphasized by Capitol Biologics' integration of advanced capabilities in cell line development, process optimization, and GMP manufacturing, all under a unified quality management system.
Darryl Sampey, President and CEO of BioFactura, underscores the significance of Capitol Biologics in aiding early-stage ventures. By providing personalized service and technical excellence, the division not only helps clients reduce time and costs but also enhances national preparedness and public health initiatives. Dr. Jeffrey Hausfeld, Chairman of the Board and CMO, articulates a vision for the new division: to accelerate the advancement of innovative therapies into clinical reality, making Capitol Biologics a vital partner in the biotechnology sector.
In addition to its manufacturing capabilities, Capitol Biologics aims to foster collaboration within the broader biotech community. By sharing BioFactura's rich expertise, the new CDMO positions itself as a problem-solving partner dedicated to addressing the unique needs of its clients. This strategic move signals a growing trend in the biopharmaceutical industry, where specialized CDMOs play a critical role in supporting the development of groundbreaking therapies.
As Capitol Biologics embarks on its mission, it is poised to make significant contributions to the biotechnology landscape. The establishment of this division reflects the increasing demand for efficient, high-quality manufacturing solutions in the biopharmaceutical sector, driven by both commercial and public health imperatives. With its focus on innovation and quality, Capitol Biologics is set to enhance the capabilities of biotechnology companies and support the broader goal of advancing health solutions.